These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26408564)

  • 1. Bilateral Facial Palsy following Ipilimumab Infusion for Melanoma.
    Altman AL; Golub JS; Pensak ML; Samy RN
    Otolaryngol Head Neck Surg; 2015 Nov; 153(5):894-5. PubMed ID: 26408564
    [No Abstract]   [Full Text] [Related]  

  • 2. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report.
    Numata S; Iwata Y; Okumura R; Arima M; Kobayashi T; Watanabe S; Suzuki K; Horiguchi M; Sugiura K
    J Dermatol; 2018 Jan; 45(1):113-114. PubMed ID: 28225147
    [No Abstract]   [Full Text] [Related]  

  • 3. Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab.
    Minor DR; Bunker SR; Doyle J
    J Clin Oncol; 2013 Jul; 31(20):e356. PubMed ID: 23733772
    [No Abstract]   [Full Text] [Related]  

  • 4. Nursing management of patients with metastatic melanoma receiving ipilimumab.
    Bryce J; Passoni C
    Oncol Nurs Forum; 2013 May; 40(3):215-8. PubMed ID: 23615135
    [No Abstract]   [Full Text] [Related]  

  • 5. [Ipilimumab-induced hypophysitis].
    Schleder S; Schreml S; Heiss P
    Rofo; 2013 Mar; 185(3):268-9. PubMed ID: 23154861
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient.
    Eckert A; Schoeffler A; Dalle S; Phan A; Kiakouama L; Thomas L
    Dermatology; 2009; 218(1):69-70. PubMed ID: 18832811
    [No Abstract]   [Full Text] [Related]  

  • 7. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
    Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
    Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment.
    Humayun MA; Poole R
    Hormones (Athens); 2016 Apr; 15(2):303-306. PubMed ID: 27376434
    [No Abstract]   [Full Text] [Related]  

  • 9. Pathologic quiz case 1. Metastasis of a superficial spreading malignant melanoma.
    Mestdagh F; Claes J; Van Marck E; Neetens I; Van de Heyning PH
    Arch Otolaryngol Head Neck Surg; 1995 Aug; 121(8):934, 936. PubMed ID: 7619425
    [No Abstract]   [Full Text] [Related]  

  • 10. Ipilimumab-Associated Retinopathy.
    Crews J; Agarwal A; Jack L; Xu D; Do DV; Nguyen QD
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):658-60. PubMed ID: 26114847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab (Yervoy) and inoperable or metastatic melanoma. More evaluation needed, in both first- and second-line use.
    Prescrire Int; 2015 Apr; 24(159):96. PubMed ID: 25941700
    [No Abstract]   [Full Text] [Related]  

  • 12. Vemurafenib-induced bilateral facial palsy.
    Shailesh FN; Singh M; Tiwari U; Hutchins LF
    J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
    Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
    Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymyalgia rheumatica occurring during treatment with ipilimumab.
    Maniu C; Kobe C; Schlaak M; Mauch C; Eming SA
    Eur J Dermatol; 2016 Oct; 26(5):513-514. PubMed ID: 27349150
    [No Abstract]   [Full Text] [Related]  

  • 15. Peripheral neuropathy associated with ipilimumab: a report of 2 cases.
    Thaipisuttikul I; Chapman P; Avila EK
    J Immunother; 2015; 38(2):77-9. PubMed ID: 25658617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Unilateral acneiform rash in facial palsy].
    Kerob D; Hennequin V; Bousquet G; Behm E; Lebbe C
    Ann Dermatol Venereol; 2010 Nov; 137(11):727-9. PubMed ID: 21074658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma.
    Koch C; Paetzold S; Trojan J
    Gastroenterology; 2012 Aug; 143(2):298, 504, 505. PubMed ID: 22709738
    [No Abstract]   [Full Text] [Related]  

  • 19. Ipilimumab-induced hypophysitis: early Australian experience.
    De Sousa SM; Long GV; Tonks KT
    Med J Aust; 2014 Aug; 201(4):198-9. PubMed ID: 25164840
    [No Abstract]   [Full Text] [Related]  

  • 20. Vemurafenib sensitivity skin reaction after ipilimumab.
    Harding JJ; Pulitzer M; Chapman PB
    N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.